Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 11/20 | 0.46 |
| ▸ | IL1B | P01584 | 2/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10199840 | 1.00 | CASP1 (0.46) | CASP1IL1BACECASP3ELANE | |
| SCHEMBL646081 | 0.86 | CASP1 (0.63) | CASP1IL1BACECASP3LCK | |
| SCHEMBL647340 | 0.86 | CASP1 (0.63) | CASP1IL1BACECASP3LCK | |
| SCHEMBL10199721 | 0.84 | CASP1 (0.47) | CASP1IL1BACECASP3 | |
| SCHEMBL10247793 | 0.84 | CASP1 (0.47) | CASP1IL1BACECASP3 | |
| SCHEMBL10247762 | 0.82 | CASP1 (0.46) | CASP1IL1BACECASP3 | |
| SCHEMBL10199406 | 0.82 | CASP1 (0.46) | CASP1IL1BACECASP3 | |
| SCHEMBL10200461 | 0.82 | CASP1 (0.52) | CASP1IL1BACECASP3LCK | |
| SCHEMBL10199689 | 0.81 | CASP1 (0.60) | CASP1IL1BACECASP3ELANE | |
| SCHEMBL10248023 | 0.81 | CASP1 (0.60) | CASP1IL1BACECASP3ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CASP1 6/4885IL1B 3/4885ACE 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.